Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi

Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart fa...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2020/09/01, Vol.59(17), pp.2155-2160
Main Authors: Tsujinaga, Shingo, Iwano, Hiroyuki, Oshino, Tomohiro, Kadosaka, Takahide, Mizuguchi, Yoshifumi, Motoi, Ko, Chiba, Yasuyuki, Koya, Taro, Temma, Taro, Kamiya, Kiwamu, Fukushima, Arata, Koizumi, Takuya, Sato, Tomoya, Takenaka, Sakae, Tada, Atsushi, Ishizaka, Suguru, Sarashina, Miwa, Omote, Kazunori, Kamada, Rui, Konishi, Takao, Sato, Takuma, Nagai, Toshiyuki, Yamashita, Hiroko, Anzai, Toshihisa
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Aged
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Atrium
Bevacizumab
Bevacizumab - adverse effects
Bevacizumab - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
cardiotoxicity
Case Report
Chemotherapy
Congestive heart failure
Epirubicin
Epirubicin - adverse effects
Epirubicin - therapeutic use
Female
Heart failure
Heart Failure - chemically induced
Heart Failure - drug therapy
Heart Failure - physiopathology
Humans
Internal medicine
Monoclonal antibodies
Targeted cancer therapy
Thromboembolism
thrombus
Treatment Outcome
Vascular endothelial growth factor
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.4792-20